Peter Attia· MD
well it was it was actually the ctep inhibitor plus Lipitor versus Lipitor alone and this was a Pfizer study which everybody thought was very cheeky of Pfizer because Lipitor was about to come off patent and their way of sort of extending the life of it was saying hey when you pair the ctap inhibitor with Lipitor it's going to have a benefit because the the background on this is that ctep Inhibitors raised HDL cholesterol so it's like we're going to take a drug Lipitor that lowers LDL cholesterol we're going to pair it with a drug that raises HDL cholesterol how could this possibly go wrong famous last words yeah so they they intended to follow follow-up patients it's going to be about almost a five-year trial four and a half years and along the way they'll have a review board that's looking at the results of the study and in this case they had a monitoring board that was looking at in this case they're looking at death all-cause mortality and they they found that 82 82 patients receiving the drug combination had died compared with only 51 on Lipitor alone and so they advised Pfizer to Halt the trial at that point which it did immediately which it was just a little over a year into the trial